Whether diabetes after kidney donation is associated with an accelerated GFR decay in the remaining kidney has not been studied. We determined the incidence of diabetes in kidney donors, and compared GFR change over time in diabetic to nondiabetic donors, in addition to the effect of diabetes mellitus (DM) on the development of proteinuria, hypertension, and endstage renal disease (ESRD). Of the 4014 donors, 309 (7.7%) developed diabetes at a median age of 56.0 years and after a median of 18 years after donation. The difference in annual estimated GFR (eGFR) change between diabetic and nondiabetic donors in the 7 years before the development of DM was À0.08 mL/min/year; p = 0.51. After DM development, the difference was À1.10 mL/min/year for diabetic donors with hypertension and proteinuria, p < 0.001; À0.19 for diabetic donors with hypertension but no proteinuria, p = 0.29; À0.75 mL/min/year for diabetic donors with proteinuria but no hypertension, p = 0.19; and À0.09 mL/min/year for diabetic donors without proteinuria or hypertension, p = 0.63. When DM was considered as a time-dependent covariate, it was associated with the development of proteinuria (hazard ratio [HR] 2.65, 95% confidence interval [CI] 1.89-3.70; p < 0.001) and hypertension (HR 2.19, 95% CI 1.74-2.75; p < 0.001). It was not, however, associated with ESRD. eGFR decline after DM development exceeds that of nondiabetic donors only in diabetic donors with concomitant proteinuria and hypertension.
Introduction
Hyperfiltration occurs in both diabetes mellitus (DM) and following reduction in renal mass (1, 2) . Post-donation DM and its effect on the development of proteinuria, hypertension, and reduced GFR in kidney donors have not been sufficiently addressed. This is important because a substantial proportion of donors donate to family members with DM, a disease that has a strong genetic component. Moreover, diabetes in the setting of reduced renal mass offers a unique opportunity to quantify the impact of hyperfiltration in people without intrinsic kidney disease. Suggestive evidence from kidney transplant recipients who receive a transplant for DM and our previous short-term study of diabetic kidney donors does not seem to indicate that there is an accelerated development of diabetic kidney disease (3) (4) (5) (6) . In fact, graft loss from DM in recipients is distinctly rare and donors who developed diabetes were, at least in the short term, not at a heightened risk for rapid progression of diabetic kidney disease (7) (8) (9) . Moreover, case series of patients with a native single kidney and DM do not seem to suggest a higher risk of diabetic nephropathy (10, 11 ).
Herein we determined the incidence of DM after donation and addressed its association with important renal outcomes including GFR decay, proteinuria, hypertension, and end-stage renal disease (ESRD).
Methods

Study population
Detailed account of the University of Minnesota donor program has been published previously (12, 13) . Exclusion criteria for donation include any proteinuria (urinary protein >150 mg/day or urinary albumin/ creatinine >30 mg/g), BMI >30 kg/m 2 unless physical examination results warranted acceptance, and diabetes. 
Exposure and outcomes
DM was determined from donors' self-report of treatment with diet, oral agents, or insulin. Donors provided the name and start date for antidiabetic medications and fasting blood sugar measurements, and hemoglobin A1c (HbA1c), when available.
To address the renal implications of DM after donation, we studied the association of DM with incident hypertension, proteinuria, rate of estimated GFR (eGFR) change before and after DM development, and ESRD. We defined proteinuria by a urinary albumin excretion rate >30 mg/g creatinine, 24 h urinary protein >200 mg/day or ≥2+ on urine dipstick tests. ESRD was defined by needing dialysis, undergoing a kidney transplant, or being placed on the deceased donor waiting list for a transplant. To calculate the eGFR, we used the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation (14) . We previously showed that the CKD-EPI equation is more precise (than the MDRD Study equation) in living kidney donors who underwent GFR measurement with iohexol (15) . Only creatinine values >6 weeks after donation were used because the goal was to model long-term trends in kidney function.
Statistical analysis
Continuous covariates were summarized as mean (standard deviation [SD] ) and categorical characteristics were summarized as frequencies (percent). To test univariable differences between donors with and without DM, we used t-tests (continuous variables) and chi-square or Fisher's tests (categorical variables). Kaplan-Meier estimation was used to determine the cumulative incidence of diabetes, hypertension, and proteinuria over time since donation. Follow-up for these time-to-event outcomes was censored at the latest of the following: latest clinical encounter, latest receipt of health survey, or information collected at time of death.
To estimate the effect of incident DM on eGFR trajectory we used linear mixed-effects models. Specifically, we fit a model with fixed effects for age at donation, gender, BMI at donation, donation year, fasting glucose level, eGFR, donor type, DM as cause of ESRD in the recipient, smoking history, race, and time since donation. Interaction terms between time and both donor type (related vs. unrelated) and eGFR were also used. Considering the post-donation compensatory increase in GFR, we allowed the eGFR trajectory to change at 15 years after donation for all donors. In addition, we allowed the eGFR trajectory to change 7 years before the DM diagnosis to allow for the fact that DM may cause changes in kidney function before clinical diagnosis, as well as at time of DM diagnosis. This linear spline basis allows for sufficient flexibility in the post-donation trajectory while remaining more interpretable than other basis expansions. The knot points at 15 years (entire cohort) and 7 years before diagnosis and at DM diagnosis were chosen based on modeling the eGFR trajectory using restricted cubic splines using the RCSPLINE macro (16) . In addition, we wanted to assess whether the eGFR trajectory once donors developed DM differed by whether the donor also had hypertension and proteinuria. Specifically, indicators for whether diabetic donors developed hypertension and proteinuria up to 5 years after DM were included in an interaction term with time from diabetes diagnosis date.
To account for correlation among repeated measurements for the same donor, we included a random subject-specific intercept and random slopes. Individual eGFR trajectories were estimated using the empirical Bayes (best linear unbiased predictors) of the random effects (17) .
In a sensitivity analysis to compare eGFR trajectories after donation, we performed matching as follows: each diabetic donor was matched to five donors who survived without DM until at least the time their respective case developed diabetes (18) . A linear mixed model was again fit while adjusting for the same fixed patient characteristics that were used for the main trajectory analysis.
We also quantified the association between DM and ESRD, proteinuria, and hypertension, by treating DM onset as a time-dependent covariate in a proportional hazard regression model. Covariates included for this analysis were age, gender, systolic blood pressure, diastolic blood pressure, BMI, fasting glucose, year of donation, smoking history, relationship to recipient, eGFR at donation, and race. Covariates were selected using backward variable selection with p < 0.05 to stay. In each model, timedependent DM and hypertension (for proteinuria and ESRD outcomes) were included in the final model regardless of significance.
For all data analyses, we used SAS version 9.4 (SAS Institute, Inc., Cary, NC). Graphics were produced in R version 3.3.2. All statistical tests were two-sided tests with p < 0.05 indicating statistical significance.
Results
Of the 4362 living kidney donors at our center, 4014 (92.0%) completed a health survey, with the latest followup occurring at an average 17.7 years (SD 12.1 years) after donation; 58.2% were women and 78.9% were related to their recipient, and mean age at donation was 39.5 (SD 11.7) years (Table 1) . At donation, the mean serum creatinine level was 0.9 (SD 0. Respondents were more likely to be women and less likely to be smokers but were otherwise comparable to nonrespondents. When comparing those who did (n = 309) and did not (n = 3705) develop DM after donation, the DM donors had a significantly higher donation BMI, serum glucose, serum creatinine, and eGFR. They were younger and more likely to be related to their recipient, to smoke, and be male (Table 1) . For the entire cohort, the mean change in BMI from donation to last follow-up was 1.97 (SD 4.2) kg/m 2 . For diabetic donors, the mean change was 3.9 (5.8) and for nondiabetic donors it was 1.8 (4.0) kg/m 2 (p < 0.001). In total, 309 (7.7%) donors developed DM during the observed follow-up at a median age of 56.0 years and after a median of 18.0 years from donation. An average of 9.2 (range 0-34.7) years of follow-up was available after DM diagnosis. The cumulative incidence of diabetes, hypertension, and proteinuria in the entire cohort is shown in Figure 1A . The incidence of DM at 10, 20, and 30 years after donation was 2.4%, 7.0%, and 14.5%, respectively. The incidence of proteinuria and hypertension was significantly higher for DM donors (log-rank p < 0.0001) in comparison to non-DM donors ( Figure 1B ). Of the 309 donors who developed DM during the observed follow-up, 186 (60.2%) developed hypertension, 52 (16.8%) developed proteinuria, and 200 (64.7%) developed either hypertension or proteinuria, before or within the first 5 years after diabetes diagnosis. To better dissect the temporal relationship between onset of DM and proteinuria, histograms depicting the time from diabetes diagnosis to diagnosis of proteinuria and hypertension is shown in Figure 2 . Most cases of proteinuria followed DM onset, whereas hypertension preceded DM in the majority. Of the 3705 nondiabetic donors, 952 (25.7%) developed hypertension, 199 (5.4%) developed proteinuria, and 1040 (28.1%) developed either condition at any point after donation.
eGFR trajectory in diabetic donors and matched controls Of all donors, 264 diabetic donors and 2717 nondiabetic donors had at least one serum creatinine value determined >6 weeks after donation and no missing covariate information, and thus were used in the subsequent analyses. Donor-specific trajectories of predicted eGFR in relation to diabetes diagnosis date are shown in Figure 3 . Of the 264 DM donors, 191 had an increased predicted eGFR immediately before diabetes in comparison to donation and 73 had a decreased predicted eGFR. In our first model, which did not consider the proteinuria and hypertension status of donors, we found that after DM diagnosis, the difference in yearly change between diabetics and nondiabetics was À0.30 mL/min/year (95% confidence interval [CI] À0.55, À0.05; p = 0.02). We next looked at eGFR change after DM development accounting for the presence of hypertension and/or proteinuria up to 5 years after diabetes. Table 2 gives the estimated coefficients from the linear mixed-effect model. Here, the difference in the yearly eGFR change between diabetic and nondiabetic donors in the 7 years before DM development was À0.08 (p = 0.51). Following DM diagnosis, only the diabetic donors with both hypertension and proteinuria had a significantly steeper eGFR decline compared to a non-DM donor over the same time period: average yearly difference À1.10 mL/min/year for diabetic donors with hypertension and proteinuria, p < 0.001; À0.19 mL/min/year for diabetic donors with hypertension but no proteinuria, p = 0.29; À0.75 mL/min/year for diabetic donors with proteinuria but no hypertension, p = 0.19; and À0.09 mL/min/year for diabetic donors without proteinuria or hypertension, p = 0.63. Figure 4A depicts the estimated mean eGFR trajectory for a representative donor who develops DM 10 years after donation by whether the donor had proteinuria or hypertension (up to 5 years after DM) as well as one who never develops DM. Estimates and standard errors for the data in this plot at 5-year intervals are presented in Table 3 .
In the matched sensitivity analysis, annual eGFR change after DM development was 0.37 mL/min/year steeper in diabetic donors (95% CI À0.72, À0.01, p = 0.045). Figure 4B depicts the change in eGFR for a representative donor with diabetes diagnosis at 10 years after donation and without diabetes based on estimates from this analysis. In total, 7.7% of donors developed DM at a median age of 56 years and thus would have to contend with diabetes and its related complications for 20 or more years. Although DM accounts for approximately half of all ESRD cases in the general population, only 12% to 22% of ESRD cases in kidney donors have been attributed to DM (13, (19) (20) (21) (22) (23) . This lower incidence of ESRD from DM in kidney donors may reflect the fact that many people who are at very high risk of DM are generally excluded from donation. In addition, kidney donors tend to be healthier. Moreover, most of ESRD from diabetes occurs in African Americans and Hispanics, which are not sufficiently represented in this analysis. The link between obesity and reduced GFR, proteinuria, and ESRD in kidney donors is strong (13, 24) . Most recently, Locke et al. reported that obese donors are almost twice more likely to develop ESRD in the first 20 years after donation (24) . On the other hand, few data exist regarding the fate of kidney donors who had elevated serum glucose level at donation. To address this, we recently compared the outcomes of donors with fasting pre-donation glucose <100, 100-109, 110-125, and >126 mg/dL (25) . These cutpoints represent what was considered normal fasting glucose in different eras according to the American Diabetes Association. Compared to donors with fasting blood sugar (FBS) <109 mg/dL, donors in the two higher categories were more likely to develop hypertension and diabetes. Donors with FBS >126 mg/dL were more likely to become proteinuric (HR 1.83, 95% CI 1.01-3.32). There were no differences in the risk of reduced eGFR among these groups. Finally, many donate to a family member with glomerulonephritis (GN). Due to its familial nature and because GN has a more aggressive course than DM, this may account for the lower percentage of ESRD caused by DM in the donor population compared to the general population. In fact, we have recently shown that most of ESRD in the first few years after donation was due to focal segmental glomerulosclerosis (23) . These data do not support the generally prevailing conviction that hyperfiltration seen in many diabetic individuals will be additive to the hyperfiltration driven by uninephrectomy to cause adverse renal consequences. The prevalence of proteinuria in diabetic donors is not different from what is reported in diabetic individuals with two kidneys nor is the prevalence of hypertension higher (26) . Moreover, the rate of GFR change in diabetic donors is similar to two-kidney hypertensive microalbuminuric diabetics such as the participants of the Irbesartan Diabetic Nephropathy Trial (27) . In that trial, participants receiving placebo experienced a 1.2 mL/min/ 1.73 m 2 per year GFR decline. Clearly, not having actual two-kidney diabetic controls in this current analysis warrants extreme caution regarding conclusions about the course of diabetes in one kidney versus two. It is possible that since hyperfiltration is nearly complete in the first few years after donation-no additive hyperfiltration is taking place by the time diabetes develops. Moreover, hyperfiltration in kidney donors is mostly due to an increase in the glomerular surface area rather than augmentation in the intraglomerular pressure such as that seen with diabetes (28) .
Consequences of post-donation DM
An average of 9.2 (range 0-34.7) years of follow-up was available after DM diagnosis. Data from the United Kingdom Prospective DM Study (UKPDS) indicate that for an individual with normoalbuminuria at onset of DM, it will take a median of 19 years before they advance to each subsequent stage of nephropathy (microalbuminuria, macroalbuminuria and, finally, elevated creatinine or ESRD); for those with microalbuminuria at DM onset it was a median of 11 years (29) . Thus for a new diabetic donor with normoalbuminuria, ESRD is unlikely to occur during the lifetime of a donor. If microalbuminuria is, however, present, ESRD would develop at a median of 22 years, which would put the diabetic donor at roughly age 80. In our series, 40% of diabetic donors received an angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blocker. These agents may account for some of the observed benign nature of their kidney function. How much effect these agents had on reduction of the degree of proteinuria and level of kidney function cannot be ascertained without performing the measurement while off these agents, which was not done here.
There are limitations to our findings: DM and hypertension were self-reported and only verified in those who provided laboratory testing and a list of their medications and records from their physicians; this was 72% of all donors. The concordance of self-reported drug-treated Time of diabetes diagnosis in Figure 4A trajectory plot.
DM and hypertension with medical record abstraction is excellent (30, 31) . ESRD in living donors is a rare event and thus we are unable to detect a difference in incidence of ESRD related to post-donation DM onset. In addition, we cannot be certain that the proteinuria observed in diabetic donors is indeed caused by DM as we do not have histologic renal confirmation or detailed retinal examination findings. Finally, most of the donors studied were white but 75% of US donors are white (32) .
Collectively, these data suggest that current routine practices in Caucasian donors that exclude prediabetics and those with strong family history of diabetic kidney disease need to be continued. The development of diabetes results in a rate of GFR decline that is faster than nondiabetic donors, only if hypertension and proteinuria are present.
